EUVIMEDEUVIMED entdecken
Crossref

Implementation of mass pharmacogenetic testing : Dihydropyrimidine dehydrogenase testing prior to fluoropyrimidine treatment for patients

Nisha Shaunak, Jessica Keen iD, Anna Kim, Munir Pirmohamed iD, William G Newman iD, Paul J Ross iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Nisha Shaunak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guy's & St Thomas NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Pharmacogenomic Testing, Antimetabolites, Antineoplastic, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Manchester NIHR BRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Pharmacogenomics enables personalization of drug therapy improving effectiveness and/or safety. Dihydropyrimidine dehydrogenase [DPYD] testing prior to fluoropyrimidine chemotherapy was commissioned by NHS England in response to an update from the Medicines and Healthcare products Regulatory Agency.

Methods

A questionnaire developed and approved by the National DPYD Working Group investigated processes of testing, receiving and responding to results. The survey was distributed to Genomics Medicine Service Alliance (GMSA) Clinical Directors and Pharmacy Senior Responsible Officers for dissemination in their geography. Data were collected June–September 2021. All hospitals delivering fluoropyrimidines across the UK were invited to participate.

Results

131/138 (94.9%) organizations reported testing all patients receiving fluoropyrimidines. In England 76.7% of hospitals sent samples to centrally commissioned genomics laboratories. In the devolved nations, 73.9% sent samples to regional genomics laboratories. Multidisciplinary staff including oncologists, independent non‐medical prescribers, clinical nurse specialists, screening pharmacists and chemotherapy nurses requested the test, checked and actioned the result. Self‐reported turnaround times varied from 10 days.

Conclusion

Through multiprofessional, national collaboration, this is the first report studying the large‐scale rollout of a nationally commissioned pharmacogenetic test. Whilst DPYD testing has been successfully implemented, there is a need to standardize and improve end‐to‐end turnaround times. This has led to the development of a best practice pathway. Critically, GMSAs must build on this implementation to deliver its priorities, in supporting equitable access to future pharmacogenomic testing across a wider cohort of therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)Pharmacogenomic TestingAntimetabolites, AntineoplasticNeoplasmsHumansSurveys and QuestionnairesPrecision MedicineFluorouracilEnglandPharmacogenetics

Stichwörter der Autor:innen

DPYDfluoropyrimidinespharmacogenomics

Substanzen

Dihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticFluorouracil

Autor:innen und Institutionen

  • Guy's & St Thomas NHS Foundation Trust, London, UK.
  • NHS South East Genomic Medicine Service Alliance, UK.
  • NHS North West Genomic Medicine Service Alliance, UK.
  • Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK.
  • Wolfson Centre for Personalised Medicine, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
  • Division of Evolution, Infection and Genomics, University of Manchester, Manchester, UK.

ORCID-Profile: Jessica Keen, Munir Pirmohamed, William G Newman, Paul J Ross

Förderung

  • Manchester NIHR BRC

Zitieren

APA

Shaunak, N., Keen, J., Kim, A., Pirmohamed, M., Newman, W. G., & Ross, P. J. (2025). Implementation of mass pharmacogenetic testing : Dihydropyrimidine dehydrogenase testing prior to fluoropyrimidine treatment for patients. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70057

Vancouver

Shaunak N, Keen J, Kim A, Pirmohamed M, Newman WG, Ross PJ. Implementation of mass pharmacogenetic testing : Dihydropyrimidine dehydrogenase testing prior to fluoropyrimidine treatment for patients. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70057

BibTeX
@article{Shaunak2025,
  author = {Shaunak, Nisha and Keen, Jessica and Kim, Anna and Pirmohamed, Munir and Newman, William G and Ross, Paul J},
  title = {Implementation of mass pharmacogenetic testing : Dihydropyrimidine dehydrogenase testing prior to fluoropyrimidine treatment for patients},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70057}
}
Kostenlos starten →